Back to Search
Start Over
PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup.
- Source :
-
Annals of Oncology . 2022 Supplement 6, Vol. 33, pS465-S465. 1p. - Publication Year :
- 2022
- Subjects :
- *PEMBROLIZUMAB
*PLACEBOS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 158120007
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.05.066